At relapse, one patient had an ABL1 kinase domain (KD) E255V mutation, one had a T3151 mutation (in a patient who was on dasatinib at the time of relapse due to the development of worsening coronary atherosclerosis), and two did not have an ABL1 KD mutation detected. The gene discussed is ABL1; the disease is coronary atherosclerosis.